Regeneran Pharmaceuticals, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Regeneran Pharmaceuticals, Inc..The latest application filed is for "bispecific anti-muc16 x anti-cd28 antibodies and uses thereof".

Company Profile

6.38.0

Regeneran Pharmaceuticals, Inc. - Tarrytown NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof Grant 11,453,721 - Murphy , et al. September 27, 2	2022-09-27
Packaging Grant D961,377 - Cook , et al. August 23, 2	2022-08-23
Genetically modified rat comprising a humanized TRKB locus Grant 11,419,318 - Mujica , et al. August 23, 2	2022-08-23
Packaging Grant D961,376 - Cook , et al. August 23, 2	2022-08-23
Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation Grant 11,419,319 - Hatsell , et al. August 23, 2	2022-08-23
Aseptic piercing system and method Grant 11,406,565 - Arnott , et al. August 9, 2	2022-08-09
Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof Grant 11,384,153 - Smith , et al. July 12, 2	2022-07-12
Method and system of identifying and quantifying a protein Grant 11,385,239 - Yan , et al. July 12, 2	2022-07-12
Humanized universal light chain mice Grant 11,357,217 - McWhirter , et al. June 14, 2	2022-06-14
Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors Grant 11,359,246 - Lotta , et al. June 14, 2	2022-06-14
Use of Raman spectroscopy in downstream purification Grant 11,358,984 - Passno , et al. June 14, 2	2022-06-14
Quantitation and modeling of quality attributes of therapeutic monoclonal antibodies Grant 11,355,217 - Xu , et al. June 7, 2	2022-06-07
Methods and systems for chromatography data analysis Grant 11,333,642 - Mao , et al. May 17, 2	2022-05-17
Methods and compositions for treating subjects having rheumatoid arthritis Grant 11,319,375 - Boyapati , et al. May 3, 2	2022-05-03
Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor Grant 11,248,044 - Donahue , et al. February 15, 2	2022-02-15
Room temperature stable lyophilized protein Grant 11,241,498 - Tang , et al. February 8, 2	2022-02-08
Mice that make heavy chain antibodies Grant 11,234,419 - Macdonald , et al. February 1, 2	2022-02-01
Non-human animals expressing pH-sensitive immunoglobulin sequences Grant 11,224,207 - McWhirter , et al. January 18, 2	2022-01-18
Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist Grant 11,214,621 - Mannent , et al. January 4, 2	2022-01-04
Perfusion bioreactor and related methods of use Grant 11,193,103 - Angelini , et al. December 7, 2	2021-12-07
Multispecific antigen-binding molecules and uses thereof Grant 11,191,844 - Andreev , et al. December 7, 2	2021-12-07
Histidine engineered light chain antibodies and genetically modified non-human animals for generating same Grant 11,192,947 - McWhirter , et al. December 7, 2	2021-12-07
Anti-VEGF protein compositions and methods for producing the same Grant 11,186,625 - Wang , et al. November 30, 2	2021-11-30
Anti-VEGF protein compositions and methods for producing the same Grant 11,174,283 - Tustian , et al. November 16, 2	2021-11-16
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor Grant 11,167,004 - Radin , et al. November 9, 2	2021-11-09
Readily isolated bispecific antibodies with native immunoglobulin format Grant 11,168,111 - Davis , et al. November 9, 2	2021-11-09
Medical device packaging and related methods Grant 11,160,918 - Cook , et al. November 2, 2	2021-11-02
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof Grant 11,155,621 - Smith , et al. October 26, 2	2021-10-26
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof Grant 11,155,633 - Kirshner , et al. October 26, 2	2021-10-26
Human antibodies to PD-L1 Grant 11,117,970 - Papadopoulos , et al. September 14, 2	2021-09-14
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants Grant 11,104,715 - Lawrence , et al. August 31, 2	2021-08-31
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof Grant 11,072,656 - Smith , et al. July 27, 2	2021-07-27
Non-human animal models of retinoschisis Grant 11,064,685 - Brydges , et al. July 20, 2	2021-07-20
Mice expressing a limited immunoglobulin light chain repertoire Grant 11,026,407 - McWhirter , et al. June 8, 2	2021-06-08
Methods of assessing antibody-drug conjugates Grant 10,976,241 - Skinner , et al. April 13, 2	2021-04-13
Mice that make V.sub.L binding proteins Grant 10,954,310 - Macdonald , et al. March 23, 2	2021-03-23
Taurine supplemented cell culture medium and methods of use Grant 10,927,342 - Johnson , et al. February 23, 2	2021-02-23
Genetically modified major histocompatibility complex mice Grant 10,869,466 - Macdonald , et al. December 22, 2	2020-12-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.